Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 128 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Breaking down changes in NHS cancer waiting times in England August 17, 2023 Can Eating Soy Cause Breast Cancer? October 19, 2021 FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Load more HOT NEWS Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... Why I Choose to Live With Gratitude During Metastatic Breast Cancer FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:...
